每经记者｜闫峰峰 每经编辑｜吴永久 2022年2月，三元生物以109.3元/股发行价登陆创业板，募资总额36.86亿元，募集资金净额35.47亿元， 成为国内赤藓糖醇行业首家上市公司。 然而，与三元生物IPO募资的热度形成鲜明对比的是，公司在上市后股价表现明显偏冷。公司在上市第 二日便破发，其后股价更是持续走弱，一度跌至20.8元。而截至1月26日，公司收盘价为28.21元，较其 前复权后的发行价69.35元仍然大幅破发。 如今三元生物的市值也仅约为56亿元，这对于一个3年多前募资近37亿元的公司来说，在A股也算罕见 了。 三元生物上市后股价表现疲弱，背后是其多项经营指标在上市后的断崖式下跌。 近日，市值约56亿元的创业板上市公司三元生物公告拟使用不超过19亿元人民币暂时闲置超募资金进行 现金管理。《每日经济新闻》记者发现，三元生物市值相对较小，却能拿出大笔资金理财并进行大手笔 分红，其背后是公司IPO募集资金带来的现金储备支撑。 三元生物2022年IPO募资总额高达36.86亿元，公司有超20亿元的IPO资金被用于补充流动资金，公司现 金及类现金的资产总计超30亿元，更是有超半数的利润来自于理财收益和利息收 ...

Investment Rating - The report assigns a "Buy" rating to the company [2] Core Insights - The company is positioned as a leader in the functional sugar segment, with significant growth potential anticipated [1] - The company has achieved a high revenue growth rate, with a projected increase in revenue from 1.38 billion RMB in 2025 to 2.22 billion RMB in 2027, reflecting a compound annual growth rate (CAGR) of 28.1% [6][44] - The company is expected to maintain a strong profit margin, with net profit projected to grow from 365 million RMB in 2025 to 611 million RMB in 2027, representing a CAGR of 30.9% [6][46] Summary by Sections 1. Market Growth Potential - The dietary fiber market shows a significant gap in global intake, indicating a strong demand for products in this category [13] - The global dietary fiber market is expected to grow at a CAGR of 10.03% from 2023 to 2030, with production projected to reach 427,000 tons and sales of 1 billion USD by 2030 [15][19] 2. Company Overview - The company has optimized its product structure, leading to improved profitability, with a notable increase in the sales proportion of high-margin resistant dextrin [7][32] - The company is the first in China to obtain production licenses for resistant dextrin and industrial-scale production of allulose, establishing a competitive edge [32][37] - The company has expanded its production capacity, with new facilities in Thailand expected to enhance its international competitiveness and revenue [40][41] 3. Profit Forecast and Investment Recommendations - Revenue forecasts for 2025-2027 are 1.38 billion RMB, 1.73 billion RMB, and 2.22 billion RMB, respectively, with corresponding growth rates of 19.7%, 25.8%, and 28.1% [44] - The company is expected to achieve net profits of 3.66 billion RMB in 2025, with a projected increase to 6.11 billion RMB by 2027, reflecting strong growth in profitability [6][46] - The report suggests a target price of 30.02 RMB per share based on a 27x PE ratio for 2026, indicating a favorable valuation compared to historical averages [46][47]

【方正食饮-王泽华团队】2026年上市公司交流会 · 食品饮料专场 #酒类及酒类渠道5家 珍酒李渡/古越龙山/舍得酒业/新华都/重庆啤酒（线上） 地点：深圳 · 好日子皇冠假日酒店 交流名单： #酒类及酒类渠道5家 珍酒李渡/古越龙山/舍得酒业/新华都/重庆啤酒（线上） #乳品5家 均瑶健康/新乳业/妙可蓝多/ 【方正食饮-王泽华团队】2026年上市公司交流会 · 食品饮料专场 领导好，方正研究所将于1/28-1/29举办上市公司交流会，团队邀请#共25家上市公司及3位行业专家交流，诚邀您 拨冗参加。 领导好，方正研究所将于1/28-1/29举办上市公司交流会，团队邀请#共25家上市公司及3位行业专家交流，诚邀您 拨冗参加。 地点：深圳 · 好日子皇冠假日酒店 交流名单： #乳品5家 均瑶健康/新乳业/妙可蓝多/一鸣食品/熊猫乳品（线上） #餐饮链： 锅圈/日辰股份（线上） #休闲食品7家： 盐津铺子/甘源食品/西麦食品/好想你/来伊份/索宝蛋白（线上）/劲仔食品（线上） #保健品4家： 百合股份/仙乐健康/民生健康/技源集团（线上） #食品添加剂3家 百龙创园/莱茵生物/晨光生物（线上） #行业专家3位 保 ...

Core Viewpoint - Huakang Co., Ltd. (605077) has a strong market presence with its products widely used in food, beverage, pharmaceutical, and daily chemical industries, demonstrating high market recognition [1] Group 1: Market Presence - The company has established long-term cooperative relationships with well-known domestic and international food and beverage enterprises, with products sold in major global markets including Europe, America, and Asia [1] - In the domestic market, the company has built a sales network covering most provinces, cities, and autonomous regions [1] Group 2: Sales Strategy - The company is expanding its domestic e-commerce market through its subsidiary, Huakang Trading, transitioning from a primarily B2B model to a combination of B2B and B2C models, creating a more comprehensive sales system [1]

Core Viewpoint - Huakang Co., Ltd. has established a strong market presence with its products widely used in various downstream industries such as food, beverages, pharmaceuticals, and daily chemicals, indicating high market recognition [2]. Group 1 - The company's products are extensively applied in food, beverage, pharmaceutical, and daily chemical industries [2]. - Huakang has built long-term cooperative relationships with well-known domestic and international companies in the food and beverage sector [2]. - The company's products are sold in major markets globally, including Europe, America, and Asia [2]. Group 2 - The primary sales method for the company is direct sales [2]. - Huakang has established a subsidiary in Europe to enhance its market reach [2].

Investment Rating - The investment rating for the company is "Buy" [1]. Core Insights - The company achieved record high performance in 2025, with revenue reaching 1.379 billion yuan, a year-on-year increase of 19.75%. The net profit attributable to shareholders was 366 million yuan, up 48.94%, and the net profit excluding non-recurring items was 361 million yuan, an increase of 55.87% [1][3]. - In Q4 2025, the company reported revenue of 410 million yuan, a 23.87% increase year-on-year, with a net profit of 101 million yuan, reflecting a 60.53% growth [1][3]. - The growth was driven by product structure optimization, cost reduction through technological advancements, and increased capacity utilization [3]. Summary by Sections Financial Performance - In 2025, the company reported total revenue of 1.379 billion yuan, with a growth rate of 19.7% expected for 2026 and 26.1% for 2027. The net profit is projected to reach 465 million yuan in 2026 and 611 million yuan in 2027, with corresponding growth rates of 27.1% and 31.3% [4]. - The gross margin is expected to be 42.3% in 2025, slightly decreasing to 40.7% in 2026, and then stabilizing at 41.1% in 2027 [4]. - The earnings per share (EPS) are forecasted to be 0.87 yuan in 2025, 1.11 yuan in 2026, and 1.45 yuan in 2027, with price-to-earnings (P/E) ratios of 28X, 22X, and 17X respectively [4]. Growth Drivers - The company is expanding its production capacity, with projects such as the "Functional Sugar Drying Expansion and Comprehensive Improvement Project" and the "Thailand Health New Food Raw Material Smart Factory Project" underway, which will enhance production capabilities and reduce costs [3]. - The introduction of new products, particularly D-Allulose sugar, is expected to drive sales growth in the food and beverage market, with significant partnerships already established [3]. Market Outlook - The global trend towards healthier food options is expected to continue, providing a favorable environment for the company's product sales to grow, with room for increased market penetration [3].

Investment Rating - The investment rating for the company is "Buy" [1] Core Insights - The company achieved record high performance in 2025, with revenue reaching 1.379 billion yuan, a year-on-year increase of 19.75%, and a net profit attributable to shareholders of 366 million yuan, up 48.94% year-on-year [1][3] - The growth was driven by product structure optimization, cost reduction through technological advancements, and increased capacity utilization [3] - The launch of new products, particularly D-alloheptulose, is expected to boost sales in the food and beverage market [3] - Ongoing capacity expansion projects are set to enhance production capabilities and support future growth [3] Financial Summary - Total revenue for 2025 is projected at 1.379 billion yuan, with a growth rate of 19.7% for 2025 and expected to reach 2.260 billion yuan by 2027 [4] - Net profit attributable to shareholders is forecasted to grow from 366 million yuan in 2025 to 611 million yuan in 2027, reflecting a compound annual growth rate of 31.3% [4] - The gross margin is expected to improve to 42.3% in 2025, with a projected EPS of 0.87 yuan for 2025, increasing to 1.45 yuan by 2027 [4]

分红方面，三元生物A股上市后累计派现7.08亿元。近三年，累计派现5.73亿元。 责任编辑：小浪快报 融资方面，三元生物当日融资买入487.91万元。当前融资余额2.73亿元，占流通市值的4.89%，融资余 额低于近一年40%分位水平，处于较低位。 融券方面，三元生物1月22日融券偿还100.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量1.25万股，融券余额34.66万元，超过近一年90%分位水平，处于高位。 资料显示，山东三元生物科技股份有限公司位于山东省滨州市滨北张富路89号,山东省滨州市滨北梧桐 十路101号，成立日期2007年1月26日，上市日期2022年2月10日，公司主营业务涉及食品添加剂"赤藓糖 醇及其复配产品"的研发、生产和销售。主营业务收入构成为：糖醇类88.22%，功能糖类8.59%，其他 类2.93%，糖苷类0.26%。 截至1月9日，三元生物股东户数1.55万，较上期增加0.76%；人均流通股8416股，较上期减少0.76%。 2025年1月-9月，三元生物实现营业收入4.76亿元，同比减少7.54%；归母净利润6739.87万元，同比减少 16.80% ...

Core Insights - The Ministry of Industry and Information Technology has announced the first batch of "Biomanufacturing Pilot Capacity Construction Platform List," with Huaxi Biological Technology (Tianjin) Co., Ltd. being recognized for its leading synthetic biology pilot platform and awarded the highest "five-star" certification [1][2] - Huaxi Biological is one of only five companies in the country to receive this five-star rating, achieving the highest certification in three core areas: cosmetics, food additives, and biopharmaceuticals, marking a significant breakthrough in China's biomanufacturing infrastructure [1][2] Company Summary - Huaxi Biological's synthetic biology pilot transformation platform has a total investment exceeding 3 billion yuan, with a building area of 40,000 square meters and equipped with 64 pilot production lines [1] - The platform can simultaneously conduct large-scale transformation experiments for six categories of bioactive substances, serving multiple strategic emerging industries, including pharmaceuticals, health, and personal care [1] Industry Summary - The pilot platform is crucial for bridging the "valley of death" in the transformation of biomanufacturing research achievements, as China's technology achievement conversion rate is only about 10%, significantly lower than that of developed countries [1][2] - The platform innovatively creates a "cell factory" industrial debugging center, utilizing an intelligent central control system for real-time monitoring and early warning analysis of production processes, and employs a "flexible production line" design to quickly adapt to different pilot needs [2] - The establishment of this five-star certification is a significant signal of the national acceleration of biomanufacturing industry layout, with plans to cultivate over 20 biomanufacturing pilot platforms by 2027 [2]

Core Viewpoint - The company, Baolingbao (002286.SZ), has a diverse client base including well-known domestic and international brands, and is expanding its product offerings in the health and nutrition sector, particularly with the approval of its lactulose raw material drug for future domestic sales [1] Group 1: Client Base - The company’s main clients include prominent brands such as Yili, Coca-Cola, Yuanqi Forest, Abbott, Feihe Dairy, Junlebao, Holley, Dongpeng Beverage, and Mixue [1] Group 2: Product Development - The core products of the company include prebiotics, dietary fibers, and sugar-reducing sweeteners, with detailed business and industry development information available in the company's 2025 semi-annual report [1] Group 3: Regulatory Approvals - In October 2025, the company obtained a production license for lactulose raw material from the Shandong Provincial Drug Administration, pending further registration with the National Medical Products Administration for domestic sales [1] - Currently, the lactulose raw material is only exported to select overseas markets, but future approvals in major countries are expected to enhance sales revenue and operational performance [1]